Abstract
Brazil has the National Immunization Program for disease prevention that offers nineteen vaccines, yet it is known that vaccination coverage according to age is not always reached. Thus, this study aimed to evaluate the vaccination coverage in the municipality of Sinop, in the Mato Grosso state and in the Brazil for meningococcal C conjugate vaccines and Hepatitis B in the period from 2015 to 2019. Method: This is a descriptive, retrospective and cross-sectional study, with data available in the Information System of the National Immunization Program. Results: Vaccination coverage for mingococcal C in children under one year in Sinop was above the target in 2015 and 2018, Mato Grosso was above only in 2015, for the booster dose only Sinop was above the target in 2016. Coverage for hepatitis B in children under 30 days of life demonstrated that Sinop had coverage above the state of Mato Grosso, which in turn was above Brazil. For children under 1 year old, only in 2016 and 2019 the state presented greater vaccination coverage at the expense of Sinop and Brazil. Conclusion: The results demonstrate that there is hesitation on the part of the population regarding vaccination, being greater in vaccines such as meningococcal C. Strengthening childcare is the key to improving the panorama of vaccine coverage.
Highlights
The In Brazil, the National ImmunizationProgram (PNI) started 48 years ago, which was developed for the organization and implementation of vaccines in the Brazilian calendar (Temporão, 2003; Lima & Pinto, 2017)
Brazil has the National Immunization Program for disease prevention that offers nineteen vaccines, yet it is known that vaccination coverage according to age is not always reached
Coverage for hepatitis B in children under 30 days of life demonstrated that Sinop had coverage above the state of Mato Grosso, which in turn was above Brazil
Summary
The In Brazil, the National ImmunizationProgram (PNI) started 48 years ago, which was developed for the organization and implementation of vaccines in the Brazilian calendar (Temporão, 2003; Lima & Pinto, 2017). In 1982, the first vaccine for hepatitis B (HepB) were licensed, which came from the plasma of patients with chronic infection, and from 1986 onwards, production was started using recombinant DNA technology (Coutinho, 2010). It was in 1998 that vaccination has been recommended in the first hours of life, and since it has been offered by the PNI in order to prevent the disease and, especially, vertical infection (Brasil, 2017; Farias et al, 2020). The denominator the population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
